ReviewOncotarget2019
Genomics applied to the treatment of breast cancer.
Review in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis.The British journal of surgery · 2021Pooled it
- Pooled it
- Circ_RPPH1 facilitates progression of breast cancer via miR-1296-5p/TRIM14 axis.Cancer biology & therapy · 2024Article
- Review
- Safety of the Breast Cancer Adjuvant Radiotherapy in Ataxia-Telangiectasia Mutated Variant Carriers.Cancers · 2024Article
- Omics-Based Investigations of Breast Cancer.Molecules (Basel, Switzerland) · 2023Review
- Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing.JAMA dermatology · 2023Article
- Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches.Frontiers in genetics · 2023Review
- Discovery of genes positively modulating treatment effect using potential outcome framework and Bayesian update.BMC medical informatics and decision making · 2022Article
- 'Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics'.Frontiers in molecular biosciences · 2022Review
- Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer.Breast care (Basel, Switzerland) · 2021Review
- Application of "omics" sciences to the prediction of bone metastases from breast cancer: State of the art.Journal of bone oncology · 2021Review
- In Silico Design and Evaluation of PRAME+FliCΔD2D3 as a New Breast Cancer Vaccine Candidate.Iranian journal of medical sciences · 2021Article
- Editorial: The Importance of Diversity in Precision Medicine Research.Frontiers in genetics · 2020Article
- 'Omics Approaches to Explore the Breast Cancer Landscape.Frontiers in cell and developmental biology · 2019Review
- Axillary Clearance Following Positive Sentinel Lymph Node Biopsy in Symptomatic Breast Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains a major health issue in the world with 1.7 million new cases in 2012 worldwide. It is the second cause of death from cancer in western countries. Genomics have started to modify the treatment of breast cancer, and the developments should become more and more significant, especially in the present era of treatment personalization and with the implementation of new technologies. With molecular signatures, genomics enabled a de-escalation of chemotherapy and personalized treatments of localized forms of estrogen-dependent breast cancers. Genomics can also make a real contribution to constitutional genetics, so as to identify mutations in a panel of candidate genes. In this review, we will discuss the contributions of genomics applied to the treatment of breast cancer, whether already validated contributions or possible future applications linked to research data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.